# Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

> **NCT03170895** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 5 (actual)

## Conditions studied

- AML
- FLT3-ITD Mutation

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Omacetaxine Mepesuccinate Injection

## Key facts

- **NCT ID:** NCT03170895
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2020-02-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170895, "Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03170895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*